08 January 2019

NICE, 10 Spring Gardens, London SW1A 2BU

Final Agenda 

The meeting will start promptly at 10:00 and is expected to finish at approximately 17:00

Please note that this agenda is final and is subject to change before the meeting.

  1. Welcome and introduction to format of meeting – Part 1 only (open session)
  2. Code of conduct for members of the public attending the meeting – Part 1 only (open session)
  3. Apologies – Part 1 only (open session)
  4. Any other business – Part 1 only (open session)
  5. Minutes from the last Committee meeting held on 15 November 2018 – Part 1 only (open session)
  6. Appraisal of Abemaciclib in combination with fulvestrant for treating advanced hormone receptor-positive, HER2-negative breast cancer [ID1339]
    • 6.1. Declarations of interest – Part 1 only (open session)
    • 6.2. Introduction by Chair Dr Jane Adam – Part 1 only (open session)
    • 6.3. Presentation by the Lead Team – Part 1 AND part 2 (open and closed session)
    • 6.4. Agreement on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) – Part 2 only (closed session)
  7. Appraisal of Ertugliflozin in a triple therapy regimen for treating type 2 diabetes [ID1160]
    • 7.1. Declarations of interest – Part 1 only (open session)
    • 7.2. Introduction by Chair Dr Jane Adam  Part 1 only (open session)
    • 7.3. Presentation by Chair Dr Jane Adam Part 1 AND part 2 (open and closed session)
    • 7.4. Agreement on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) – Part 2 only (closed session)
  8. Appraisal of Ertugliflozin as monotherapy and in dual therapy for treating Type 2 diabetes [ID1158]
    • 8.1. Declarations of interest – Part 1 only (open session)
    • 8.2. Introduction by Chair Dr Jane Adam  Part 1 only (open session)
    • 8.3. Presentation by Chair Dr Jane Adam  Part 1 AND part 2 (open and closed session)
    • 8.4. Agreement on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) – Part 2 only (closed session)
  9. Appraisal of Pertuzumab for adjuvant treatment of early HER2-positive breast cancer [ID1192] - 

    The nature of the discussion for this topic is commercially sensitive and will take place in a part 2 session (part 2 sessions are closed to public observers).

    • 9.1. Declarations of interest – Part 2 only (closed session)
    • 9.2. Introduction by Chair Dr Jane Adam – Part 2 only (closed session)
    • 9.3. Presentation by Chair Dr Jane Adam – Part 2 only (closed session)
    • 9.4. Agreement on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) – Part 2 only (closed session)

To print an agenda, please right click and select 'Print' from the menu.

Date, time and venue of next meeting

The next meeting will take place on Tuesday 12 March 2019 at 10:00am, at NICE, 10 Spring Gardens, London SW1A 2BU 

Please note all timings are approximate.

How to register

  • Click on the register link below and complete the registration form, selecting the topics you would like to attend.
  • You will receive an automated email response when you submit the registration form. If you do not receive this automated response your registration request has not been received, and you will need to complete and submit the registration form again.
  • Registration will close on Friday 14 December 2018Please note that it may not be possible to accept late requests. 
  • Should you have queries regarding attending this meeting, please contact the Meetings in Public Coordinator Ana Uribe Echeverry.
  • Registrants wishing to conduct a research study on committee meetings and/or NICE processes will require prior permission. Contact the NICE Enquiry Handling team at nice@nice.org.uk.
  • Further information about conducting research is also available in our common questions and answers about meetings in public document.

 

Registration period: 30 November 2018 to 14 December 2018
Registration is closed.